Abstract:What's new? Anti‐HER2 agents are associated with occurrences of blurred vision, conjunctivitis, and other adverse effects on the eyes. Such ocular adverse events, however, are often underestimated and lack comprehensive evaluation. Here, using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), the authors conducted a retrospective investigation of ocular toxicity risk linked to anti‐HER2 agents. Analyses reveal varying degrees of association between ocular toxicity and anti‐HER2 drugs. Notably, risk was significantly elevated in association with antibody drugs compared to tyrosine kinase inhibitors. Furthermore, several ocular toxicity signals were identified that currently are absent from product labels. Anti‐human epidermal growth factor receptor 2 (HER2) agents have exhibited pronounced tumor‐inhibitory activity, yet the accompanying ocular toxicity has frequently been underestimated. We aim to conduct a comprehensive comparative analysis of ocular toxicity risk related to various anti‐HER2 agents. We executed a retrospective pharmacovigilance investigation based on the FDA Adverse Event Reporting System (FAERS) database, covering the period from Q2 2018 to Q1 2023. The disproportionality analysis was performed to assess ocular toxicity risk. Multivariate logistic regression was implemented to mitigate potential biases. Moreover, the time to onset of ocular toxicity was also evaluated. A total of 3467 ocular adverse event (AE) reports concerning anti‐HER2 agents were collected. At the preferred term (PT) level, there were 69 positive signals, among which excessive eye blinking, abnormal sensation in the eye, and asthenopia presented a significant risk. In comparison to tyrosine kinase inhibitors (TKIs), antibody drugs were associated with a broader range of ocular disorders at Standardized MedDRA Queries (SMQ)levels, including conjunctival disorders, corneal disorders, ocular infections, ocular motility disorders, optic nerve disorders, and retinal disorders. In terms of onset time, pertuzumab displayed an earlier onset at 21.5 days, while trastuzumab deruxtecan had the latest at 91.5 days. In summary, our study reveals varying degrees of ocular toxicity related to anti‐HER2 agents, with a significantly higher risk observed in antibody drugs. Additionally, novel ocular toxicity signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings.

Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports

Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database

Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database

Ocular Surface Side Effects of Novel Anticancer Drugs

[Ocular surface adverse reactions of antitumor-targeted drugs]

The side effects of platinum-based chemotherapy drugs: a review for chemists.

Hypersensitivity Reactions to oxaliplatin: incidence and management

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)

Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Neuro-ophthalmic complications of modern anti-cancer drugs

Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience

Risk of ocular adverse events with aromatase inhibitors

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy

Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine

Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity

Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies

Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study